Biotech

All Articles

FDA areas Kezar lupus test in grip adhering to 4 individual deaths

.The FDA has actually positioned Kezar Life Sciences' lupus test on hold after the biotech warned 4 ...

Phase 3 Intellectual Rock trial hits SMA goal, sending out stock up 200%

.A phase 3 trial of Academic Stone's spinal muscular atrophy (SMA) applicant has struck its own main...

CAMP 4 is actually latest to eye IPO, while Upstream describe $182M plan

.RNA biotech CAMP4 Therapeutics has marked out think about a $67 thousand IPO, with inflammation-foc...

Galecto purchases leukemia medicine, goes down bone tissue cancer cells asset in pivot

.A year after the failing of an idiopathic lung fibrosis applicant sent Galecto on a hunt for redemp...

Judo throws down $100M to knock senseless renal condition

.Taking the floor covering is Judo Biography, an up-and-coming biotech equipped along with $one hund...

AstraZeneca spends CSPC $100M for preclinical heart problem drug

.AstraZeneca has paid CSPC Drug Group $one hundred thousand for a preclinical heart disease medicati...

Zephyrm seeks Hong Kong IPO to money period 3 tissue treatment tests

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, submission (PDF) for an I...

Frazier Lifestyle Sciences gets $630M for little, mid-cap biotechs

.Frazier Everyday life Sciences has sourced a better $630 thousand for its own fund focused on small...

GigaGen gets as much as $135M BARDA money to hammer botulism

.Antibody enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its specialis...

GPCR company Septerna declare IPO on stamina of preclinical information

.Septerna is about to figure out how a biotech without "any sort of relevant professional records" f...